The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
This funding will help the start-up consolidate its position as a one-stop destination for pet parents as they holistically reimagine the entire pet care ecosystem
Cipla has reported consolidated financial results for the period ended September 30, 2021
Filing marks first protein-based vaccine submitted to MHRA for authorization
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
Second interchangeable biosimilar product approved by agency
_256_384.jpg)
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
Subscribe To Our Newsletter & Stay Updated
